Canadian FAIT Research
Get Updates
Treatment Options

Future Research in Food Allergy Treatment

Food allergy care is changing faster than at any point in the past few decades. Here's a plain-language look at what researchers are working on, and why that matters for BC families today.

Three Parallel Tracks

Different delivery methods, all under active study.

A skin patch, a biologic medication, and a toothpaste-based approach are each being studied as ways to build tolerance differently than SLIT or OIT.

A fast-moving field

Even families who decide SLIT or OIT aren't the right fit today may find that the landscape looks different in a few years. Researchers are actively studying new ways to deliver allergen immunotherapy, new medications that work alongside it, and entirely new approaches to how the immune system is retrained. None of what follows is a promise of a future cure — but it is a real, active area of medical research.

Emerging therapies and delivery methods

🩹

Epicutaneous immunotherapy (skin patches)

Instead of a dose eaten or held under the tongue, epicutaneous immunotherapy (EPIT) delivers a tiny amount of allergen through a patch worn on the skin. It's being studied as a potentially gentler entry point, with a peanut patch currently in late-stage clinical review in North America.

💊

Biologic medications

A newer category of medication works by targeting the antibody (IgE) involved in allergic reactions rather than the food itself. One such medication received FDA approval in 2024 to help reduce the severity of reactions from accidental exposure to multiple foods — sometimes used on its own, and sometimes studied alongside immunotherapy to help lower the risk of reactions during treatment.

🪥

Toothpaste-based immunotherapy

An early-stage approach, sometimes called oral mucosal immunotherapy, delivers a tiny, measured amount of allergen through daily brushing with a specially made toothpaste. In a small first-phase safety trial in adults with peanut allergy, participants tolerated the treatment well with no moderate or severe reactions — promising, but still early research, not yet available outside of clinical trials.

Researchers are also studying combination approaches — for example, pairing a biologic medication with OIT or SLIT to see whether that combination can make the build-up phase safer or faster — as well as longer-term follow-up on how long tolerance lasts after treatment ends.

Why clinical research participation matters

Every treatment option described on this site — SLIT, OIT, and the therapies above — exists today because families before yours chose to take part in clinical research. Trials are how new approaches get tested for safety and effectiveness before they become part of everyday care, and hospital-based and university allergy research programs across Canada continue to enroll new studies.

If you're curious whether a current trial might be relevant to your child, that's a good question to bring to your allergist, or to explore at one of our information sessions.

Attend a Free Information Session Back to Treatment Options
A researcher in a lab measuring a small sample, representing ongoing food allergy research
Treatment decisions should always be discussed with qualified healthcare professionals, such as your child's doctor or allergist. This page is educational information, not medical advice.

Related reading: Sublingual Immunotherapy (SLIT), Oral Immunotherapy (OIT), and our FAQ.

Sources